Consequently, strategies that co-target GLUT1 and insulin signaling to restrict glucose flux may synergize with pro-oxidant therapies, offering a promising therapeutic avenue for HNSCC. The gene discussed is SLC2A1; the disease is head and neck squamous cell carcinoma.